<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Gencer, B</dc:creator>
  <dc:creator>Carballo, D</dc:creator>
  <dc:creator>Nanchen, D</dc:creator>
  <dc:creator>Koskinas, K</dc:creator>
  <dc:creator>Klingenberg, R</dc:creator>
  <dc:creator>Raeber, L</dc:creator>
  <dc:creator>Auer, R</dc:creator>
  <dc:creator>Carballo, S</dc:creator>
  <dc:creator>Heg, D</dc:creator>
  <dc:creator>Windecker, S</dc:creator>
  <dc:creator>Luscher, T F</dc:creator>
  <dc:creator>Matter, C M</dc:creator>
  <dc:creator>Rodondi, N</dc:creator>
  <dc:creator>Mach, F</dc:creator>
  <dc:date>2019</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">&lt;jats:title&gt;Abstract&lt;/jats:title&gt;
               &lt;jats:sec&gt;
                  &lt;jats:title&gt;Background&lt;/jats:title&gt;
                  &lt;jats:p&gt;The gradual implementation of evidence-based treatment strategies has improved outcomes in patients with acute coronary syndromes (ACS). The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) was published on June 3rd, 2015, but its relevance on real life practice has not been explored.&lt;/jats:p&gt;
               &lt;/jats:sec&gt;
               &lt;jats:sec&gt;
                  &lt;jats:title&gt;Methods&lt;/jats:title&gt;
                  &lt;jats:p&gt;We analyzed a prospective Swiss cohort of 6266 patients hospitalized for ACS between 2009 and 2017. The primary endpoints were the ezetimibe use overall or in combination with high-intensity statin at discharge and at one year after ACS. Secondary endpoint was LDL-C target achievement at one year in a subsample of 2984 patients. Relative Ratios (RR) were used to assess changes in primary endpoints before and after the publication of IMPROVE-IT, adjusting for age, sex, pre-existing diabetes, history of myocardial infarction, baseline low-density lipoprotein cholesterol (LDL-C) and attendance to cardiac rehabilitation.&lt;/jats:p&gt;
               &lt;/jats:sec&gt;
               &lt;jats:sec&gt;
                  &lt;jats:title&gt;Results&lt;/jats:title&gt;
                  &lt;jats:p&gt;The period following the publication of the IMPROVE-IT trial was associated with an overall increase in the use of ezetimibe at discharge (from 1.8% to 3.8%, P&amp;lt;0.001, adjusted RR 2.85, 95% CI 1.90–4.25) and at one year (from 5.0% to 13.8%, P&amp;lt;0.001, adjusted RR 3.00, 95% CI 2.40–3.75). Before IMPROVE-IT trial, ezetimibe use at one year was stable around 5%, then steadily increased after its publication until 20% for patients included in 2017. The combination of high-intensity statin and ezetimibe increased from 0.9% to 2.1% at discharge (P&amp;lt;0.001, adjusted RR 3.35, 95% CI 1.90–5.89) and from 2.1% to 7.8% at one year (P&amp;lt;0.001, adjusted RR 3.98, 95% CI 2.90–5.47). The period following the publication of the IMPROVE-IT trial was associated with an improvement of LDL-C target &amp;lt;1.8 mmol/L (adjusted RR 1.37, 95% CI 1.12–1.68).&lt;/jats:p&gt;
               &lt;/jats:sec&gt;
               &lt;jats:sec&gt;
                  &lt;jats:title&gt;Conclusion&lt;/jats:title&gt;
                  &lt;jats:p&gt;After the publication of the IMPROVE-IT trial, the use of ezetimibe was increased by three-fold in a large contemporary cohort of ACS patients, concomitant with an improved LDL-C target achievement.&lt;/jats:p&gt;
               &lt;/jats:sec&gt;</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/340</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/eurheartj/ehz748.0180</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0195-668X</dc:relation>
  <dc:source>European Heart Journal. - Oxford University Press (OUP). - 2019, vol. 40, no. Supplement_1</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Cardiology and Cardiovascular Medicine</dc:subject>
  <dc:title xmlns:ns2="xml" ns2:lang="en">P1222Intensification of lipid lowering therapy before and after publication of the IMPROVE-IT trial: A temporal analysis from the SPUM-ACS cohort</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
